Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
← catalyst calendarNCT03833154 · readout in 803 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
724actual
Sites
209
Countries
Australia, Belgium, Brazil +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-03-06 | actual | When the study began enrolling |
| Primary completion | 2028-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2019-02-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small-Cell Lung
Interventions
- Drug: Durvalumab — also filed as MEDI4736
- Other: Placebo
- Drug: (Osimertinib cohort, single-arm, open-label separate cohort)
Primary outcomes
what the primary-completion date above is the date OFProgression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 in subpopulation of patients with Stage I/II NSCLC
measured from randomization up to 6 years
4-year Progression-Free Survival (4y-PFS) by ICR according to RECIST 1.1 criteria
measured from treatment start up to 5 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed